Oestrogens are essential factors in the growth and development of normal breast tissue (Laron et al., 1989) and act via specific nuclear receptors (ERs) (Gorski et al., 1986) . In the normal breast oestrogens act as mitogens and also induce the progesterone receptor, which is required for development and differentiation (Horwitz et al., 1985) . However, it has long been known that oestrogenLs have an important role in the development and subsequent progression of human breast cancer (Seibert & Lippman, 1982) . More recently evidence has emerged suggesting that oestrogenic effects are mediated to some degree by peptide growth factors and their receptors (Lippman & Dickson, 1989) .
These peptide growth factors along with their receptors are now being increasingly recognised for the role that they play in the growth and differentiation of both normal (Rowe & Friesen, 1984) and malignant tissue (Lippman et al., 1988) . Of these, the epidermal growth factor receptor (EGFR) is of particular interest in human breast cancer. Human EGFR is a high-affinity transmembrane receptor glycoprotein with a molecular weight of 170,000 (Cohen et al., 1982) . It consists of an external ligand-binding domain, a transmembrane section and a cytoplasmic or internal domain that contains a tyrosine-specific protein kinase (Downward et al., 1984) .
Many studies in recent years have shown an inverse relationship between ER and EGFR in female human breast cancer (Sainsbury et al., 1985; Toi et al., 1989; Lewis et al., 1990) . EGFR expression in human breast cancer is associated with a number of features of poor prognosis, including high tumour grade (Hainsworth et al., 1991) , lymphatic invasion (Toi et al., 1989 (Toi et al., , 1990 , lymph node involvement (Hainsworth et al., 1991) and markers of increased cellular proliferation such as Ki-67 (Toi et al., 1990) . It has also been shown to be significantly associated with resistance to hormone therapy , reduced relapse-free period (Lewis et al., 1990; Nicholson et al., 1990) and reduced overall survival . There are some studies that dispute these findings, and these have been extensively reviewed elsewhere (Klijn et al., 1992) .
This inverse relationship with all its implications for prognosis has been the subject of intense study. Initial investigations involved the use of biochemical ligand-binding assays and revealed that ER could be detected in 60-80% of human breast cancers (McGuire et al., 1975) and EGFR in 45% (Klijn et al., 1992) . These studies involved the homogenisation of sample tissue and thus were unable to address the issues of tumour heterogeneity, such as which cells were receptor positive (e.g. benign or malignant) or what proportion of cancer cells were receptor positive. The development of monoclonal antibodies and immunocytochemical assays specific for ER (King & Greene, 1984) and EGFR (Waterfield et al., 1982) on frozen sections addressed these issues. The results of the ER immunocytochemical assay (ER-ICA) using the monoclonal antibody H222 shows high concordance with the biochemical ligand-binding assays (McClelland et al., 1986) . ER is immunolocalised in the nuclei of target cells (King & Green, 1984; King et al., 1985) , and human breast cancer is found to have a heterogeneous population of ER-positive cells and ER-negative cells (King et al., 1985) . The EGFR immunocytochemical assay (EGFR-ICA) using the monoclonal antibody EGFR1 (Waterfield et al., 1982) localises EGFR on the cellular membrane and this also displays a heterogeneous distribution (Toi et al., 1989) .
Studies have tried to examine the heterogeneous distribution of ER and EGFR at the individual cellular level by examining serial cross-sections of frozen breast cancer (Toi et al., 1989) . The results suggested that EGFR was selectively stained on ER-negative cells and cell groups in tumours categorised to be positive for both. However, the technique of taking serial cross-section samples is open to the criticism that the same cell or cell groups are not being examined in different sections. To address this issue we have developed a dual immunocytochemical assay (D-ICA) that is able to stain for both ER and EGFR on a single 5 jLm frozen section sample of tumour cell lines (Sharma et al., 1994 
Materials
The tissues used for analysis were obtained from 22 patients who had previously been categorised to be positive for ER and EGFR by immunocytochemical assay. Of the 22 patients (age range 35-81 years), nine were premenopausal and 13 were post-menopausal (Table I ). All the samples were obtained from primary breast cancer patients undergoing mastectomy or wide local excision or from excision of locoregional recurrences in patients who had not received any form of adjuvant therapy.
The samples were snap frozen within 30 min of excision in liquid nitrogen or dry ice. They were then placed in individual flexible plastic moulds that contained a semiviscous freezing compound (OCT, Miles Laboratories, Naperville, IL, USA), snap frozen to -70°C in dry ice and stored at -70°C. Five micron cryostat sections were cut and thaw mounted onto poly-L-lysine tissue adhesive-coated glass slides and immediately either underwent the fixation procedure for the ER-ICA, EGFR-ICA and D-ICA or were stained with haematoxylin-eosin for histological examination. All 22 samples were deemed histologically assessable on the haematoxylin-eosin preparation. Repeat ER-ICA and EGFR-ICA and the D-ICA were performed on all 22 samples.
ER-ICA
The cryostat sections were fixed in 3.7% formaldehyde-PBS (0.01 M phosphate-buffered saline) for 15 min, washed twice for 5 min in PBS, fixed at -10°C in absolute methanol for 6 min followed by immersion in acetone at -10°C for 3 min then washed again in PBS (2 x 5 min). The sections were then stored -20°C in a glycerol-sucrose specimen storage medium for up to 7 days prior to staining. The reagents used for staining were obtained in kit form (ER-ICA monoclonal, Abbott Laboratories, North Chicago, IL, USA). After blocking non-specific binding with normal goat serum (NGS, 15 min), the staining procedure involved sequential incubations, with intervening PBS washes (2 x 5 min), with rat monoclonal anti-ER or control normal rat IgG (30 min), bridging goat anti-rat IgG (30 min), rat peroxidase-antiperoxidase complex (30 min) and diaminobenzidine (DAB)-hydrogen peroxide-chromogen substrate solution (6 min). The indirect peroxidase-anti-peroxidase procedures of the assay are fully described elsewhere (Walker et al., 1988) . The slides were then rinsed in deionised water (2 x 5 min), counterstained with 1% aqueous methyl green (5 min) washed again in deionised water (1 min), dehydrated in graded ethanols (50%, 70%, 90%, 100%), air dried for 1 h, cleared in xylene and coverslipped using a xylene-soluble mountant.
Parallel control sections using normal rat IgG antiserum were run to check for non-specific staining. Inclusion of control slides of MCF-7 cells enabled inter-assay variations to be monitored. Brown nuclear staining is observed in ERpositive cells following the ER-ICA.
EGFR-ICA The cryostat sections were air dried for 1 h prior to storage in a sealed box at -70°C for up to 7 days prior to assay. The slides were rehydrated in PBS followed by fixation in 50:50 chloroform-acetone at 4°C (10 min) followed by washing in PBS (2 x 5 min). The sections were then incubated with 10% normal goat serum (NGS) in PBS to block non-specific antibody binding. Excess serum was removed and mouse monoclonal primary anti-EGFR antibody (EGFR1, Amersham International, UK) or a control mouse anti-sheep erythrocyte antibody (MASE, seraLab, UK) was added (60 min). EGFR1 was added at 1 ig ml-' with 10% NGS and 5% normal human serum (NHS) in PBS. This monoclonal antibody detects the native folded external domain of human EGFR and does not compete with EGF for binding with EGFR. The control antibody was added at a similar concentration to parallel sections of each specimen. Following the primary incubation the slides were washed in PBS (3 x S min) followed by incubation with rabbit anti-mouse peroxidase-conjugated antiserum (Dakopatts, UK) at 1:50 dilution in PBS and containing 10% NGS and 5% NHS (30 min). The slides were then washed in PBS (3 x 5 min) and immunoreactivity was revealed by incubation with 3-amino, 9-ethylcarbazole (AEC) containing hydrogen peroxide obtained in kit form (Immustain, DPC, Oxfordshire, UK) for 10 min. The slides were then washed in tap water (2 x 5 min), counterstained with 1% aqueous methyl green (5 min), washed again in deionised water (1 min) and immediately coverslipped using Aquamount (Gurr, Poole, UK).
Inclusion of control slides of an EGFR-positive breast cancer determined by both radioligand binding and immunocytochemical assays enabled inter-assay variations to be monitored. Red membrane-associated and cytoplasmic staining is observed in EGFR-positive cells following the EGFR-ICA.
D-ICA The cryostat sections were fixed and stored for up to 7 days as previously described (Sharma et al., 1993) . The slides then underwent the sequential steps as per the ER-ICA until the incubation with the DAB-hydrogen peroxide chromogen substrate solution, which was applied for 10 min. This extended incubation period achieved maximal colour production and was followed by washing in deionised water (5 min) then PBS (5 min). The sections were then incubated with 20% NGS and 10% NHS in PBS for 30 min to block non-specific antibody binding. Following the removal of excess serum EGFR1 at 2pgml-' with 10% NGS and 5% NHS in PBS was added to the slides that had received the rat monoclonal anti-ER antiserum for 60 min. MASE, at a similar concentration, was added to the slides that had received the control normal rat IgG for 60 min. The EGFR1 had been preincubated with 2.5 volumes of NHS and the MASE with two volumes of NHS for 30 min prior to final dilutions. The sections were then washed in PBS (3 x 5 min) prior to adding the rabbit anti-mouse peroxidase-conjugated antiserum at 1:50 dilution in PBS with 10% NGS and 5% NHS (30 min). This had also been preincubated with 2.5 volumes of NHS for 30 min prior to final dilution. The remaining steps were as per the EGFR-ICA with the exception that the incubation with AEC lasted 30min.
Assessment and scoring
The sections were examined, using an Olympus BH2 light microscope with a dual-viewing attachment, by two observers (A.S. and R.M.) and scored according to the intensity of staining and proportion of cells stained. For ER, scores 0-3 were allocated by 0 = no staining; 1 = weak nuclear staining; 2 = moderate nuclear staining; and 3 = strong nuclear staining. For EGFR, scores 0-3 were allocated by 0 = no staining; 1 = faint cytoplasmic reactivity; 2, distinct cytoplasmic or weak membrane reactivity and 3 = strong membrane reactivity. A percentage estimation of cancer cells stained was made for each category and the final result was obtained by the summation of all cells that displayed any reactivity (1 + 2 + 3).
Statistical analysis was performed by using Spearman's rank correlation.
Results ER-ICA and EGFR-ICA In agreement with the previous ER-ICA results, brown nuclear ER staining was immunolocalised in all 22 cases. The proportion of ER-ICA-positive cells was highly variable between patients, with positivity ranging from 10% to 90% (mean = 49%, Figure 1 and Table I ). There was marked heterogeneity in staining intensity between individual cancer cells.
Similarly, red membrane-associated and cytoplasmic EGFR staining was also immunolocalised in all 22 cases. Positivity ranged from 2% to 70% (mean = 21%, Figure 2 and Table I ). Heterogeneity between individual cancer cells was less apparent than with ER staining. No staining was observed on the control slides in either assay.
D-ICA
Using the dual ER and EGFR assay, the patterns of immunostaining were essentially similar to those previously described using the single-assay procedures. Thus, brown nuclear ER staining was immunolocalised in all 22 cases and displayed a similar heterogeneous pattern to that seen following the ER-ICA (Figure 3) , with positivity ranging from 10% to 90% (mean 46.5%, Figure 1 and Table I ). Red membraneassociated and cytoplasmic EGFR staining was immunolocalised in 20/22 (90.9%) cases (Figure 4 ) with positivity ranging from 0% (two cases) to 80% (mean= 19.5%, Figure 2 and Table I ). There was a significant correlation between the single and dual assays in determining both the ER content (r, = 0.801, P <0.001) and 30  30  20  5  43  Pre  40  10  70  10  6  43  Pre  40  10  30  10  7  45  Pre  60  5  70  5  8  45  Pre  20  5  30  10  9  48  Pre  10  10  20  0  10  52  Post  30  60  20  30  11  58  Post  50  10  50  5  12  59  Post  90  5  90  5  13  59  Post  50  10  50  40  14  61  Post  50  10  50  10  15  61  Post  30  70  20  80  16  62  Post  60  5  60  5  17  63  Post  60  40  40  50  18  65  Post  50  20  50  20  19  67  Post  50  30  50  20  20  72  Post  80  20  80  20  21  74  Post  50  40  50  30  22  81  Post  60  2  60  0 the EGFR content (r,=0.831, P<0.001). (Figure 5) . Summation of the proportion of cells expressing either ER or EGFR never exceeded 100% in either the single or dual assays for any individual patient (Table I) .
In this small select group of double-positive patients we found no significant inverse linear relationship between ER and EGFR in either the single assays (Figure 6 , r, = -0.163) or the dual assay (Figure 7 , r, = -0.249). With the exception of two patients EGFR positivity did not exceed 40%.
Discussion
The present study is the first to describe a dual immunocytochemical assay that will stain for both ER and EGFR on single 5 ym frozen section samples of clinical human breast cancer specimens. The results of staining for ER and EGFR following the D-ICA are similar to those achieved in the two single assays of proven prognostic significance (McClelland et al., 1986; Lewis et al., 1990 ) with only small variations in the proportion of tumour cells being detected as positive. Such relatively minor variations may result from observer errors, which are inherent in immunocytochemical procedures (McClelland et al., 1991) , or may be due to tumour heterogeneity, which is well documented (Walker et al., 1988) .
Using the dual assay, three phenotypes have been observed in our series of 22 ER-positive/EGFR-positive samples; ER + /EGFR-cells, ER-/EGFR + cells and ER-/EGFRcells. Importantly, no ER + /EGFR + cells were identified, despite the proven ability of this assay to detect such cells when they have been artificially constructed by transfection procedures (Sharma et al., 1994) . These data suggest that ER and EGFR are mutually exclusive within an individual cancer cell in vivo, a conclusion that is supported by studies examining the expression of these receptors in serial crosssection analysis (Toi et al., 1989 ). An alternative explanation is that ER+ /EGFR + cells were not detected because of the relatively small number of cases examined. However, it is difficult to accrue large numbers of double-positive tumours as these represent between only 4% (Bilous et al., 1992) 37% (Bevilacqua et al., 1990) (Ro et al., 1988; Watts et al., 1992) Figure 7 Relationship between ER and EGFR in the D-ICA. (Lee et al., 1990) , have also shown that treatment of ERpositive cell lines by progestins (Ewing et al., 1989) and 12-O-tetradecanoyl phorbol 13-acetate increases EGFR binding and mRNA levels with concomitant decline in ER binding and mRNA. These data suggest that final receptor expression may be determined by direct regulation of one receptor gene by the product of the other and/or reciprocal control by a common regulator that has opposite effects on these receptors at the transcriptional or posttranscriptional level. The degree to which these findings can be applied to the in vivo situation is unclear, although it has been shown that EGFR mRNA is found more commonly in ER-negative than in ER-positive breast cancer biopsies (Travers et al., 1988) .
Significantly, it is now well established that oestrogen binding to ER initiates the transcription of various mRNAs, including transforming growth factor x (TGF-x), a ligand for EGFR (Roberts et al., 1983) . Since TGF-x/EGFR binding causes down-regulation of EGFR by means of receptor internalisation (De Larco & Todaro, 1980) , the induction of TGF-o in ER-positive tumours would tend to suppress EGFR levels. Certainly, EGFR content is higher in the ER-negative tumours (Bolufer et al., 1990) , and the present study has shown that in 20/22 cases (90.9%) EGFR expression was 40% or less in these double-positive tumours.
In addition to the ER + /EGFR-and ER-/EGFR + phenotypes, the current study has also identified ER-/ EGFR-cells. Such cells were also observed in our in vitro studies (Sharma et al., 1993) and may be a consequence of ER being a cell cycle-related product (Bouzubar, 1991) .
These cell culture studies have shown that MCF-7 cells in Go are frequently ER negative and are only induced to express ER as they progress through the cell cycle (Bouzubar, 1991 (Walker et al., 1988) . This has led to the suggestion that they may represent a resting cell population (Nicholson, 1992) .
Although, as yet, no single robust theory has evolved to fully explain the inverse relationship found between ER and EGFR, it is evident that the emergence of wholly ER -/ EGFR + tumours heralds a poor outlook for the breast cancer patient with poor response to endocrine measures . In this light, we are currently applying our D-ICA to samples before, during and at the time of relapse from endocrine therapy to examine the expression of ER+/EGFR-, ER-/EGFR+ and ER-/EGFR-phenotypes. These studies may aid our understanding of the cellular mechanisms leading to hormone independence and endocrine resistance.
